Aggressive systemic mastocytosis |
|
Amylose AL : contribution aux études cliniques et thérapeutiques et à la modélisation expérimentale |
|
Analysis of Epstein-Barr virus (EBV) transcriptome by next generation sequencing (NGS) in human lymphoma cells and exosomes, particularly in angioimmunoblastic T cell lymphoma (AITL). |
|
L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature |
|
[Bevacizumab therapy for Poems syndrome] |
|
Bladder neuropathy and gastric paralysis in polyarteritis nodosa associated with hepatitis B virus |
|
Blood stem cell transplantation to treat cystic lung light chain deposition disease. |
|
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease |
|
Caractéristiques cliniques, biologiques et facteurs pronostiques de la néphropathie à cylindres myélomateux : analyse de la population de l’étude MYRE |
|
Cardiac amyloidosis: updates in diagnosis and management |
|
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial |
|
A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation |
|
CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. |
|
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients |
|
Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment |
|
Contribution in the understanding of monoclonal immunoglobulin deposition diseases pathophysiological mechanisms. |
|
Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home. |
|
Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. |
|
[Current treatment of AL amyloidosis] |
|
Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method |
|
Denosumab for treatment of hypercalcemia of malignancy. |
|
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma |
|
Diabetes insipidus revealing primary malignant non-Hodgkin's lymphoma of bone |
|
Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes. |
|
Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. |
|
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk |
|
Efficacité d’un traitement court par MGAD avec radiothérapie en sandwich en première ligne des lymphomes NK/T localisés |
|
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. |
|
Efficacy of sandwich mgad chemotherapy combined with radiotherapy in localized newly diagnosed extranodal nk/t-cell lymphoma. |
|
European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis |
|
Évaluation des différentes techniques d'épuration des chaines légères dans la néphropathie à cylindres myélomateux et chez l'insuffisant rénal chronique hémodialysé |
|
Evaluation of BC-3 and BCP-1 cell lines in immunofluorescence assay to detect HHV-8 antibodies in Kaposi's sarcoma, multiple myeloma and other groups. |
|
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group |
|
Extranodal natural killer/T-cell lymphoma: advances in the management |
|
Functional characterization of neurotensin type 2 receptor in cell death-resistance of chronic lymphocytic leukemia B cells. |
|
Gammapathie monoclonale de signification rénale et microangiopathie thrombotique : à propos de cinq cas |
|
Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients |
|
HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents |
|
Hepatocyte growth factor measurement in AL amyloidosis. |
|
HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma |
|
Hodgkin's disease after transplantation |
|
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. |
|
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. |
|
Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein. |
|
Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease? |
|
Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. |
|
Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis |
|
Left ventricular and atrial function in systemic light chains amyloidosis: an echocardiography and cardiac magnetic resonance comparison |
|
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study |
|
Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma |
|
Lymphomes malins et syndrome des antiphospholipides non simultanés : quatre observations |
|
A major turning point in NK/T-cell lymphoma? |
|
Maladie de dépôts de chaînes légères et lourdes d'immunoglobulines monoclonales de type Randall (LHCDD) : caractéristiques cliniques, histologiques et évolutives |
|
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma |
|
Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review. |
|
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes |
|
[New insights in the treatment of myeloma with renal failure] |
|
Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool |
|
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. |
|
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma |
|
Presence of membrane platelet-activating factor receptors on B cells of chronic B cell leukaemia patients |
|
Prevention of infections during primary immunodeficiency |
|
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. |
|
Prognosis of acquired hemophilia in older people |
|
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis |
|
Purpura thrombopénique immunologique de l'adulte de plus de 60 ans : à propos d'une série monocentrique de 68 cas |
|
[Randall-type monoclonal immunoglobulin deposition disease: From diagnosis to treatment]. |
|
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress] |
|
Reply to S. Girnius et al. |
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial |
|
Role of genetic and acquired factors in the pathophysiology of C3 glomerulopathy. |
|
Rôles des facteurs génétiques et acquis dans la physiopathologie des glomérulopathies à dépôts de C3 |
|
Senile systemic amyloidosis: definition, diagnosis, why thinking about? |
|
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. |
|
Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units. |
|
Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis |
|
T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B-cells due to ZAP70 overexpression in patient T-cells. |
|
T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study |
|
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? |
|
Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series |
|
Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival |
|
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial |
|